DOP2006000145A - Derivados de pirido [20,3-d] pirimidina su preparación, aplicación en terapeútica . - Google Patents

Derivados de pirido [20,3-d] pirimidina su preparación, aplicación en terapeútica .

Info

Publication number
DOP2006000145A
DOP2006000145A DO2006000145A DO2006000145A DOP2006000145A DO P2006000145 A DOP2006000145 A DO P2006000145A DO 2006000145 A DO2006000145 A DO 2006000145A DO 2006000145 A DO2006000145 A DO 2006000145A DO P2006000145 A DOP2006000145 A DO P2006000145A
Authority
DO
Dominican Republic
Prior art keywords
therapeutics
derivatives
preparation
application
pirido
Prior art date
Application number
DO2006000145A
Other languages
English (en)
Inventor
Pierre Casellas
Claude Muneaux
Samir Jegham
Bernard Bourrie
Pierre Perreaut
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of DOP2006000145A publication Critical patent/DOP2006000145A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion tiene como objetivo derivados de pirido[2,3-d]pirimidina, su preparacion y su aplicacion en terapeutica. Estos compuestos son potencialmente utiles para tratar trastomos de la proliferacion celular.
DO2006000145A 2005-07-01 2006-06-26 Derivados de pirido [20,3-d] pirimidina su preparación, aplicación en terapeútica . DOP2006000145A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0507032A FR2887882B1 (fr) 2005-07-01 2005-07-01 Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique

Publications (1)

Publication Number Publication Date
DOP2006000145A true DOP2006000145A (es) 2008-01-31

Family

ID=36096420

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000145A DOP2006000145A (es) 2005-07-01 2006-06-26 Derivados de pirido [20,3-d] pirimidina su preparación, aplicación en terapeútica .

Country Status (41)

Country Link
US (2) US7504406B2 (es)
EP (2) EP2020410B1 (es)
JP (1) JP4472009B2 (es)
KR (1) KR101298344B1 (es)
CN (2) CN101213196B (es)
AR (1) AR054812A1 (es)
AT (1) ATE423119T1 (es)
AU (1) AU2006264801B2 (es)
BR (1) BRPI0613020A2 (es)
CA (1) CA2610794C (es)
CR (1) CR9568A (es)
CY (2) CY1110457T1 (es)
DE (1) DE602006005246D1 (es)
DK (2) DK1902054T3 (es)
DO (1) DOP2006000145A (es)
EA (1) EA014312B1 (es)
EC (1) ECSP078011A (es)
ES (2) ES2322101T3 (es)
FR (1) FR2887882B1 (es)
HK (1) HK1122797A1 (es)
HR (2) HRP20090236T1 (es)
IL (1) IL187900A0 (es)
JO (1) JO2550B1 (es)
MA (1) MA29561B1 (es)
ME (1) ME01813B (es)
MX (1) MX2007016239A (es)
MY (1) MY143089A (es)
NO (1) NO20080418L (es)
NZ (1) NZ564072A (es)
PA (1) PA8684801A1 (es)
PE (1) PE20070139A1 (es)
PL (2) PL2020410T3 (es)
PT (2) PT1902054E (es)
RS (2) RS53211B (es)
SI (2) SI2020410T1 (es)
TN (1) TNSN07440A1 (es)
TW (1) TWI321566B (es)
UA (1) UA92021C2 (es)
UY (1) UY29645A1 (es)
WO (1) WO2007003765A1 (es)
ZA (1) ZA200711032B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
WO2010042998A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
CA2740484C (en) 2008-10-17 2021-09-21 Akaal Pharma Pty Ltd S1p receptors modulators and their use thereof
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
CN103204822B (zh) * 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
EP2638911A1 (en) 2012-03-14 2013-09-18 Sanofi Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
CN103833771A (zh) * 2012-11-22 2014-06-04 天津滨江药物研发有限公司 作为蛋白激酶Mek抑制剂的苯并五元杂环化合物及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
JPH04128276A (ja) 1990-09-19 1992-04-28 Pfizer Pharmaceut Co Ltd アミノベンゾサルタム誘導体およびその用途
DE69515898T2 (de) * 1994-11-14 2000-08-17 Warner Lambert Co 6-ARYL-PYRIDO[2,3-d]PYRIMIDINE UND -NAPHTHYRIDINE ZUR HEMMUNG DER DURCH PROTEIN-TYROSIN-KINASE HERVORGERUFENEN ZELLVERMEHRUNG
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AR030044A1 (es) * 2000-01-25 2003-08-13 Warner Lambert Co Pirido (2,3-d ) pirimidin-2,7-diaminas inhibidores de quinasas
EE200200506A (et) * 2000-03-06 2004-02-16 Warner-Lambert Company 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
BR0112857A (pt) 2000-08-04 2005-02-09 Warner Lambert Co Compostos 2-(4-piridil)amino-6-dialcoxifenil-pirido-[2,3-d]pirimidin- 7-onas
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
AU2002952453A0 (en) * 2002-11-01 2002-11-21 Novogen Research Pty Ltd Aminated isoflavonoid derivatives and uses thereof
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US8338435B2 (en) * 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections

Also Published As

Publication number Publication date
DK2020410T3 (en) 2014-03-24
EP1902054B1 (fr) 2009-02-18
CN101213196B (zh) 2011-09-07
AR054812A1 (es) 2007-07-18
JP4472009B2 (ja) 2010-06-02
DE602006005246D1 (de) 2009-04-02
US20080176874A1 (en) 2008-07-24
EP2020410B1 (fr) 2013-12-18
PE20070139A1 (es) 2007-03-07
CN102260258A (zh) 2011-11-30
TNSN07440A1 (en) 2009-03-17
TW200745102A (en) 2007-12-16
HRP20090236T1 (en) 2009-05-31
CY1110457T1 (el) 2015-04-29
FR2887882B1 (fr) 2007-09-07
EA200800223A1 (ru) 2008-06-30
CN101213196A (zh) 2008-07-02
FR2887882A1 (fr) 2007-01-05
EP1902054A1 (fr) 2008-03-26
EA014312B1 (ru) 2010-10-29
CA2610794A1 (fr) 2007-01-11
CA2610794C (fr) 2012-02-21
PA8684801A1 (es) 2007-01-17
ES2322101T3 (es) 2009-06-16
ZA200711032B (en) 2009-04-29
RS53211B (en) 2014-08-29
UA92021C2 (ru) 2010-09-27
DK1902054T3 (da) 2009-06-15
ME01813B (me) 2014-09-20
MA29561B1 (fr) 2008-06-02
CR9568A (es) 2008-02-20
ECSP078011A (es) 2008-01-23
NO20080418L (no) 2008-03-28
AU2006264801A1 (en) 2007-01-11
ES2450067T3 (es) 2014-03-21
TWI321566B (en) 2010-03-11
PT1902054E (pt) 2009-04-22
PT2020410E (pt) 2014-03-20
JP2008544975A (ja) 2008-12-11
ATE423119T1 (de) 2009-03-15
KR101298344B1 (ko) 2013-08-20
JO2550B1 (en) 2010-09-05
SI2020410T1 (sl) 2014-04-30
AU2006264801B2 (en) 2012-05-10
CN102260258B (zh) 2015-01-07
EP2020410A1 (fr) 2009-02-04
HK1122797A1 (en) 2009-05-29
UY29645A1 (es) 2007-01-31
US8008310B2 (en) 2011-08-30
HRP20140246T1 (hr) 2014-06-20
WO2007003765A1 (fr) 2007-01-11
IL187900A0 (en) 2008-03-20
SI1902054T1 (sl) 2009-06-30
US20090163522A1 (en) 2009-06-25
US7504406B2 (en) 2009-03-17
KR20080021714A (ko) 2008-03-07
PL1902054T3 (pl) 2009-07-31
MY143089A (en) 2011-03-15
PL2020410T3 (pl) 2014-05-30
BRPI0613020A2 (pt) 2010-12-14
MX2007016239A (es) 2008-03-06
RS50781B (sr) 2010-08-31
NZ564072A (en) 2012-02-24
CY1114989T1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
CR9568A (es) DERIVADOS DE PIRIDO[2,3-d]PIRIMIDINA, SU PREPARACION, SU APLICACION EN TERAPEUTICA
UY29439A1 (es) Nuevos compuestos
CY1117743T1 (el) Διυποκατεστημενα οκταϋδροπυρρολο [3,4-c]πυρρολια ως ρυθμιστες υποδοχεα ορεξινης
CY1116574T1 (el) Ετεροαρυλο υποκατεστημενες πυρρολο[2,3-β]πυριδινες και πυρρολο[2,3-β]πυριμιδινες ως αναστολεις κινασης janus
ECSP11010904A (es) Compuestos de pirrolo[2,3-d]pirimidina
ECSP12011855A (es) COMPUESTOS DE pIrrolo[2,3-d]pIrimidinA
CL2008001709A1 (es) Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
MXPA03001511A (es) Imidazol-5-il-2-amino-pirimidinas como agentes para la inhibicion de la proliferacion celular.
MX2008008152A (es) Compuestos heterociclicos biciclicos.
BRPI0814529A2 (pt) Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
BRPI0615270A2 (pt) pirazol fundido como inibidores de p38 map cinase
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
SG148192A1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
GB0522082D0 (en) Formulations
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
CL2011000832A1 (es) Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.
AR056279A1 (es) Derivados de aril 1,4- pirazina sustituidos, composicion farmaceutica y un metodo in vitro
DK2059521T3 (da) Pyrazolo[1,5-A]pyrimidiner, fremgangsmåder, anvendelse og sammensætninger
CL2008001974A1 (es) Compuestos derivados de ciclopenta[d]pirimidina inhibidores de la quinasa akt; proceso de preparacion; kit farmaceutico; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, hiperproliferativas, cardiovasculares, neurode genarativas, entre otras.